Quintiles IMS Holdings, Inc. (NYSE:Q) Files An 8-K Entry into a Material Definitive Agreement

Item1.01 Entry into a Material Definitive Agreement.

On February23, 2017, Quintiles IMS Incorporated (the Issuer), a
wholly-owned subsidiary of Quintiles IMS Holdings, Inc.
(QuintilesIMS), entered into a purchase agreement with the
representative of the purchasers named therein, relating to the
issuance and sale of 1.425 billion in gross proceeds of senior
notes due 2025 bearing interest at a rate of 3.25%. The
consummation of the notes offering is subject to market and other
conditions.

Item8.01 Other Events.

On February23, 2017, QuintilesIMS issued a press release
announcing the pricing of the notes offering. A copy of the press
release is attached as Exhibit 99.1 to this Current Report on
Form 8-K.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits.

About Quintiles IMS Holdings, Inc. (NYSE:Q)

Quintiles IMS Holdings Inc, formerly Quintiles Transnational Holdings Inc., is a provider of biopharmaceutical development services and commercial outsourcing services. It is engaged in the development and commercialization of pharmaceutical therapies. Its segments include Product Development and Integrated Healthcare Services. Its Product Development segment is a contract research organization and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations, and provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions.

Quintiles IMS Holdings, Inc. (NYSE:Q) Recent Trading Information

Quintiles IMS Holdings, Inc. (NYSE:Q) closed its last trading session up +0.77 at 78.12 with 1,954,538 shares trading hands.